Routes of
administration oral PubChem CID 9952446 Molar mass 392.49 g/mol | CAS Number 625820-83-9 ChemSpider 8128056 | |
 | ||
Legal status US: Investigational New Drug Synonyms LY-503,430; (R)-4'-[1-fluoro-1-methyl-2-(propane-2-sulfonylamino)-ethyl]-biphenyl-4-carboxylic acid methylamide | ||
LY-503,430 is an ampakine drug developed by Eli Lilly.
LY-503,430 produces both nootropic and neuroprotective effects, reducing brain damage caused by 6-hydroxydopamine or MPTP and also increasing levels of the neurotrophic factor BDNF in the brain, particularly in the substantia nigra, hippocampus and striatum. It is orally active and the main application it is currently being developed for is treatment of Parkinson's Disease although it has also been proposed to be useful in the treatment of Alzheimer's Disease, depression and schizophrenia.
References
LY-503,430 Wikipedia(Text) CC BY-SA